

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



华科资本
WEALTHKING INVESTMENTS

WEALTHKING INVESTMENTS LIMITED

華科資本有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1140)

FURTHER EXTENSION OF COMPLETION OF THE LOAN CAPITALISATION AND THE SUBSCRIPTIONS INVOLVING ISSUE OF NEW SHARES UNDER THE SPECIFIC MANDATE

References are made to the announcements of Wealthking Investments Limited (the “**Company**”) dated 31 December 2021 and 12 April 2022, and the circular of the Company dated 2 March 2022 (the “**Circular**”) in relation to, among other things, the Loan Capitalisation and the Subscriptions. Terms used herein shall have the same meanings as defined in the Circular unless the context requires the otherwise.

As at the date of this announcement, due to additional time is required for completion of the Loan Capitalisation and the Subscriptions, the Company, Chunda, Subscriber A and Subscriber B have agreed to further extend the completion date for the Loan Capitalisation and the Subscriptions to on or before 31 May 2022. The parties have entered into second supplemental agreements for further extension of completion date, and save and except for the aforesaid, all other terms and conditions of each of the Loan Capitalisation Agreement, the Subscription Agreement A and the Subscription Agreement B remain unchanged and in full force and effect in all respects.

The Company will make further announcement to update the Shareholders as to the status of Completion as and when appropriate.

By order of the Board
Wealthking Investments Limited
Liu Zhiwei
Executive Director and Chairman

Hong Kong SAR, 13 May 2022

As at the date of this announcement, the Board comprises one executive Director, namely, Dr. Liu Zhiwei; two non-executive Directors, namely Dr. Fu Weigang and Dr. Wang Shibin; and three independent non-executive Directors, namely, Mr. Chen Yuming, Mr. Yan Xiaotian and Mr. Zhao Kai.